title: Impact of statin therapy on coronary intervention for non-ST elevation acute coronary syndrome with decreased low-density lipoprotein cholesterol.
abstract: OBJECTIVE
  The benefits of treating patients with acute coronary syndrome (ACS) with statins are well established. This study investigated the effects of statins on patients who presented with low levels of low-density lipoprotein (LDL) cholesterol, were diagnosed with non-ST elevation ACS, and subsequently underwent percutaneous coronary interventions (PCI).
  
  
  METHODS
  From 2000 to 2003, 87 patients(mean age 68 +/- 10 years, 69 males, 18 females) underwent PCI because of non-ST elevation ACS, and had low LDL cholesterol on presentation. These patients were divided into two groups: those who had been taking statins (S-group, n = 46), and those not taking statins, or controls (C-group, n = 41). Only patients whose LDL cholesterol was < 100 mg/dl at admission (average: 82 +/- 12 mg/dl) were included in the study. Troponin-T (TnT), creatine kinase (CK), CK-MB, and high-sense C reactive protein (hs-CRP) were measured before and 6 hr after PCI. The two groups were evaluated at 6 months clinical follow-up.
  
  
  RESULTS
  There was no difference in these markers before PCI in both groups. TnT and CK-MB in the S-group at 6 hr post-PCI were significantly decreased compared to those of the C-group (0.45 +/- 1.34 vs 1.40 +/- 2.37 ng/ml, respectively, for TnT, p = 0.04; 17.2 +/- 45.5 vs 81.3 +/- 157.2 IU/l, respectively, for CK-MB, p = 0.02). Major adverse cardiac events (MACE) defined as death, myocardial infarction, congestive heart failure and target lesion revascularization were evaluated after 6 months. There was no difference in MACE between the two groups.
  
  
  CONCLUSIONS
  Statin treatment before PCI in patients with non-ST elevation ACS demonstrated beneficial effects such as less myocardial damage, even though both groups presented with low LDL cholesterol levels. However, no significant effect on MACE was seen at 6 months after PCI.
authors: Minneapolis Heart Institute and Foundation, 920 East 28th Street Suite 620, Minneapolis, MN 55407, USA. harahide@aol.com
authors: Hidehiko
authors: H
authors: Hara
authors: Masato
authors: M
authors: Nakamura
authors: Itaru
authors: I
authors: Yokouchi
authors: Keiko
authors: K
authors: Kimura
authors: Naohiko
authors: N
authors: Nemoto
authors: Shingo
authors: S
authors: Ito
authors: Tsuyoshi
authors: T
authors: Ono
authors: Masanori
authors: M
authors: Shiba
authors: Masamichi
authors: M
authors: Wada
authors: Takahiro
authors: T
authors: Tsuji
authors: Hirotaka
authors: H
authors: Komatsu
authors: Raisuke
authors: R
authors: Iijima
authors: Rintaro
authors: R
authors: Nakajima
authors: Masaya
authors: M
authors: Yamamoto
authors: Masato
authors: M
authors: Yamamoto
authors: Takashi
authors: T
authors: Yoshitama
authors: Takuro
authors: T
authors: Takagi
authors: Hisao
authors: H
authors: Hara
authors: Kaoru
authors: K
authors: Sugi
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D008078:Cholesterol, LDL / Q000097:blood*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy / Q000628:therapy*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors